-
Jefferies Highlights Clinically Meaningful Data From Ultragenyx On KRN23
Tuesday, September 20, 2016 - 1:46pm | 352Read More...Following the presentation of KRN23 data by Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) Monday, Jefferies noted the longer follow-up data is clinically meaningful, supporting filing for a EU conditional approval by 2016. Elaborating on the data, equity analyst Gena Wang noted that data from the...
-
Ultragenyx Reports Positive Phase 2 Study Data
Monday, September 19, 2016 - 11:16am | 298Read More...Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) revealed positive interim data from the second-stage study of KRN23 for tumor-induced osteomalacia (TIO) treatment. The company indicated its interim data at 24 weeks from the first eight patients showed KRN23 improved serum phosphorus levels and bone...
-
Ultragenyx Pharmaceutical Spikes 4% Following Release Of Positive Phase 2 Data
Thursday, April 21, 2016 - 12:28pm | 238Read More...Shares of Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) gained more than 4 percent on Thursday after company reported positive interim data from a Phase 2 study. Ultragenyx Pharmaceutical focuses on the development of novel products for rare and ultra-rare diseases. The company announced that...
-
Baird Buying Ultragenyx And BioMarin
Tuesday, March 8, 2016 - 2:54pm | 542Read More...Baird has initiated coverage on Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) with an Outperform rating, citing diversified pipeline with multiple near-term catalysts. It also upgraded BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to Outperform with a $110 price target. Ultragenyx Ultragenyx's...
